Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (FluMist) in HIV-Infected Children and Adolescents
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
A PHASE1/PHASE2 clinical study on HIV Infections and Influenza, this trial is completed. The trial is conducted by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .